The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control

Dimitri J Pournaras, Clare Glicksman, Royce P Vincent, Shophia Kuganolipava, Jamie Alaghband-Zadeh, David Mahon, Jan H R Bekker, Mohammad A Ghatei, Stephen R Bloom, Julian R F Walters, Richard Welbourn, Carel W le Roux, Dimitri J Pournaras, Clare Glicksman, Royce P Vincent, Shophia Kuganolipava, Jamie Alaghband-Zadeh, David Mahon, Jan H R Bekker, Mohammad A Ghatei, Stephen R Bloom, Julian R F Walters, Richard Welbourn, Carel W le Roux

Abstract

Gastric bypass leads to the remission of type 2 diabetes independently of weight loss. Our hypothesis is that changes in bile flow due to the altered anatomy may partly explain the metabolic outcomes of the operation. We prospectively studied 12 patients undergoing gastric bypass and six patients undergoing gastric banding over a 6-wk period. Plasma fibroblast growth factor (FGF)19, stimulated by bile acid absorption in the terminal ileum, and plasma bile acids were measured. In canine and rodent models, we investigated changes in the gut hormone response after altered bile flow. FGF19 and total plasma bile acids levels increased after gastric bypass compared with no change after gastric banding. In the canine model, both food and bile, on their own, stimulated satiety gut hormone responses. However, when combined, the response was doubled. In rats, drainage of endogenous bile into the terminal ileum was associated with an enhanced satiety gut hormone response, reduced food intake, and lower body weight. In conclusion, after gastric bypass, bile flow is altered, leading to increased plasma bile acids, FGF19, incretin. and satiety gut hormone concentrations. Elucidating the mechanism of action of gastric bypass surgery may lead to novel treatments for type 2 diabetes.

Figures

Fig. 1.
Fig. 1.
A, Schematic illustration of the anatomy and canulation of the canine model. A gastrostomy tube was placed into the duodenum close to the ampulla of Vater. The common bile duct was ligated and the gallbladder canulated to allow drainage of bile. B, Schematic illustration of the functional anatomy of the bile in ileum group. Transections 1 cm proximal and distal to the drainage point of the common bile duct were performed. The proximal and distal ends of the transected duodenum were anastomosed end to end and continuity restored. The segment of the duodenum containing the common bile duct was anastomosed side to side to the distal jejunum, 10 cm proximally to the terminal ileum.
Fig. 2.
Fig. 2.
Fasting plasma FGF19 concentrations (median and interquartile ranges) at d 0, 4, and 42 in six gastric banding patients (white bars) and 12 gastric bypass patients (black bars). *, P < 0.05 Mann-Whitney U test. Preop, Preoperatively.
Fig. 3.
Fig. 3.
Fasting total plasma bile acid concentrations at d 0, 4, and 42 in six gastric banding patients (white bars) and 12 gastric bypass patients (black bars). *, P < 0.05 Mann-Whitney U test. Preop, Preoperatively.
Fig. 4.
Fig. 4.
A, AUC for the postprandial GLP-1. B, AUC for postprandial PYY response after 400 g of food in dogs pre- or postoperatively either receiving food alone without bile (food), bile alone without food (bile), or food and bile in combination (food + bile).*, P < 0.05. The time course of the postprandial response for GLP-1 (C) and PYY (D).
Fig. 5.
Fig. 5.
Plasma GLP-1 (A) and PYY (B) levels in rats that had bile draining into their duodenum or bile draining into their ileum.
Fig. 6.
Fig. 6.
A, Weight of rats in bile-in-duodenum (solid line) and bile-in-ileum (broken line) groups before and up to 28 d after surgery. B, Food intake of bile-in-duodenum (solid line) and bile-in-ileum (broken line) rats before and up to 28 d after surgery. *, P < 0.05.

References

    1. Claudel T, Staels B, Kuipers F. 2005. The farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 25:2020–2030
    1. Garg A, Grundy SM. 1994. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 121:416–422
    1. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. 2008. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31:1479–1484
    1. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. 2008. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168:1531–1540
    1. Bays HE, Goldberg RB, Truitt KE, Jones MR. 2008. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 168:1975–1983
    1. Guzelian P, Boyer JL. 1974. Glucose reabsorption from bile: evidence for a biliohepatic circulation. J Clin Invest 53:526–535
    1. Kreymann B, Williams G, Ghatei MA, Bloom SR. 1987. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300–1304
    1. Katsuma S, Hirasawa A, Tsujimoto G. 2005. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 329:386–390
    1. Pournaras DJ, Osborne A, Hawkins SC, Vincent RP, Mahon D, Ewings P, Ghatei MA, Bloom SR, Welbourn R, le Roux CW. 2010. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and two year outcomes. Ann Surg 252:966–971
    1. Polyzogopoulou EV, Kalfarentzos F, Vagenakis AG, Alexandrides TK. 2003. Restoration of euglycemia and normal acute insulin response to glucose in obese subjects with type 2 diabetes following bariatric surgery. Diabetes 52:1098–1103
    1. Pournaras DJ, le Roux CW. 2009. Obesity, gut hormones, and bariatric surgery. World J Surg 33:1983–1988
    1. Ballantyne GH, Longo WE, Savoca PE, Adrian TE, Vukasin AP, Bilchik AJ, Sussman J, Modlin IM. 1989. Deoxycholate-stimulated release of peptide YY from the isolated perfused rabbit left colon. Am J Physiol 257:G715–G724
    1. Izukura M, Hashimoto T, Gomez G, Uchida T, Greeley GH, Jr, Thompson JC. 1991. Intracolonic infusion of bile salt stimulates release of peptide YY and inhibits cholecystokinin-stimulated pancreatic exocrine secretion in conscious dogs. Pancreas 6:427–432
    1. Adrian TE, Ballantyne GH, Longo WE, Bilchik AJ, Graham S, Basson MD, Tierney RP, Modlin IM. 1993. Deoxycholate is an important releaser of peptide YY and enteroglucagon from the human colon. Gut 34:1219–1224
    1. Patti ME, Houten SM, Bianco AC, Bernier R, Larsen PR, Holst JJ, Badman MK, Maratos-Flier E, Mun EC, Pihlajamaki J, Auwerx J, Goldfine AB. 2009. Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity 17:1671–1677
    1. Jansen PL, van Werven J, Aarts E, Berends F, Janssen I, Stoker J, Schaap FG. 2011. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig Dis 29:48–51
    1. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. 2008. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7:678–693
    1. De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. 2003. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J Biol Chem 278:39124–39132
    1. Yamagata K, Daitoku H, Shimamoto Y, Matsuzaki H, Hirota K, Ishida J, Fukamizu A. 2004. Bile acids regulate gluconeogenic gene expression via small heterodimer partner-mediated repression of hepatocyte nuclear factor 4 and Foxo1. J Biol Chem 279:23158–23165
    1. Ma K, Saha PK, Chan L, Moore DD. 2006. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116:1102–1109
    1. Watanabe M, Houten SM, Mataki C, Christoffolete MA, Kim BW, Sato H, Messaddeq N, Harney JW, Ezaki O, Kodama T, Schoonjans K, Bianco AC, Auwerx J. 2006. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 439:484–489
    1. Han SI, Studer E, Gupta S, Fang Y, Qiao L, Li W, Grant S, Hylemon PB, Dent P. 2004. Bile acids enhance the activity of the insulin receptor and glycogen synthase in primary rodent hepatocytes. Hepatology 39:456–463
    1. Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA. 2002. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 143:1741–1747
    1. Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ. 2011. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621–1624
    1. Mráz M, Lacinová Z, Kaválková P, Haluzíková D, Trachta P, Drápalová J, Hanušová V, Haluzík M. 2011. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment. Physiol Res 60:627–636
    1. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, Smith RO, Görgün CZ, Hotamisligil GS. 2006. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313:1137–1140
    1. le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A, Laurenius A, Lönroth H, Fändriks L, Ghatei MA, Bloom SR, Olbers T. 2007. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246:780–785
    1. Laferrère B, Swerdlow N, Bawa B, Arias S, Bose M, Oliván B, Teixeira J, McGinty J, Rother KI. 2010. Rise of oxyntomodulin in response to oral glucose after gastric bypass surgery in patients with type 2 diabetes. J Clin Endocrinol Metab 95:4072–4076
    1. Pournaras DJ, Jafferbhoy S, Titcomb DR, Humadi S, Edmond JR, Mahon D, Welbourn R. 2010. Three hundred laparoscopic Roux-en-Y gastric bypasses: managing the learning curve in higher risk patients. Obes Surg 20:290–294
    1. O'Brien PE, Dixon JB, Laurie C, Anderson M. 2005. A prospective randomized trial of placement of the laparoscopic adjustable gastric band: comparison of the perigastric and pars flaccida pathways. Obes Surg 15:820–826
    1. Tagliacozzi D, Mozzi AF, Casetta B, Bertucci P, Bernardini S, Di Ilio C, Urbani A, Federici G. 2003. Quantitative analysis of bile acids in human plasma by liquid chromatography-electrospray tandem mass spectrometry: a simple and rapid one-step method. Clin Chem Lab Med 41:1633–1641
    1. Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR. 2003. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941–948
    1. Jackson RJ, Davis WB, Macdonald I. 1977. The energy values of carbohydrates: should bomb calorimeter data be modified? Proc Nutr Soc 36:90A
    1. Näslund E, Grybäck P, Hellström PM, Jacobsson H, Holst JJ, Theodorsson E, Backman L. 1997. Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. Int J Obes Relat Metab Disord 21:387–392
    1. Ellrichmann M, Kapelle M, Ritter PR, Holst JJ, Herzig KH, Schmidt WE, Schmitz F, Meier JJ. 2008. Orlistat inhibition of intestinal lipase acutely increases appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin, and peptide YY concentrations. J Clin Endocrinol Metab 93:3995–3998
    1. Bueter M, Löwenstein C, Olbers T, Wang M, Cluny NL, Bloom SR, Sharkey KA, Lutz TA, le Roux CW. 2010. Gastric bypass increases energy expenditure in rats. Gastroenterology 138:1845–1853
    1. Stylopoulos N, Hoppin AG, Kaplan LM. 2009. Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats. Obesity 17:1839–1847
    1. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. 2005. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217–225
    1. Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang DY, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. 2003. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 17:1581–1591
    1. Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD, Finck BN, Burgess SC, Mangelsdorf DJ, Kliewer SA. 2011. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway. Cell Metab 13:729–738

Source: PubMed

3
订阅